Research Article

Systems Approaches to Modeling Chronic Mucosal Inflammation

Mridul Kalita, Bing Tian, Boning Gao, Sanjeev Choudhary, Thomas G. Wood, Joseph R. Carmical, Istvan Boldogh, Sankar Mitra, John D. Minna, and Allan R. Brasier

1 Sealy Center for Molecular Medicine, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA
2 Department of Internal Medicine, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA
3 Hamon Center for Therapeutic Oncology Research, Department of Internal Medicine Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
4 Institute for Translational Sciences, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA
5 Departments of Biochemistry and Molecular Biology, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA
6 Microbiology and Immunology, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555, USA

Correspondence should be addressed to Allan R. Brasier; arbrasie@utmb.edu

Received 12 June 2013; Revised 8 August 2013; Accepted 9 August 2013

Academic Editor: Tao Huang

Copyright © 2013 Mridul Kalita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The respiratory mucosa is a major coordinator of the inflammatory response in chronic airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). Signals produced by the chronic inflammatory process induce epithelial mesenchymal transition (EMT) that dramatically alters the epithelial cell phenotype. The effects of EMT on epigenetic reprogramming and the activation of transcriptional networks are known, its effects on the innate inflammatory response are underexplored. We used a multiplex gene expression profiling platform to investigate the perturbations of the innate pathways induced by TGF-β in a primary airway epithelial cell model of EMT. EMT had dramatic effects on the induction of the innate pathway and the coupling interval of the canonical and noncanonical NF-κB pathways. Simulation experiments demonstrate that rapid, coordinated cap-independent translation of TRAF-1 and NF-κB2 is required to reduce the noncanonical pathway coupling interval. Experiments using amantadine confirmed the prediction that TRAF-1 and NF-κB2/p100 production is mediated by an IRES-dependent mechanism. These data indicate that the epigenetic changes produced by EMT induce dynamic state changes of the innate signaling pathway. Further applications of systems approaches will provide understanding of this complex phenotype through deterministic modeling and multidimensional (genomic and proteomic) profiling.

1. Introduction

Respiratory epithelial cells provide the principal barrier of the airways, facilitating gas exchange and mucociliary particulate clearance and are the major source of protective airway lining fluid [1, 2]. In the presence of injury, inflammation, and airway remodeling, signal transduction pathways induce global epigenetic reprogramming events to induce type II epithelial-mesenchymal transition (EMT) within a so-called epithelial mesenchymal trophic unit [3–7]. In the setting of cellular transformation, EMT is also implicated in cancer metastasis. During EMT, epithelial cells lose apicobasal polarity and decrease the expression of intercellular tight junctions (TJs), adherens junctions (AJs), and desmosomes [8, 9]. These changes lead to disruption of adhesion of the basal epithelial layer and allow cellular penetration into an extracellular matrix (ECM), promoting enhanced ECM production and fibrosis. As a result, type II EMT plays a central role in normal tissue response to injury and tissue remodeling and repair, whereas type III EMT is linked to cancer dissemination [10].

Despite the key role of EMT in normal tissue development and repair, dysregulated EMT has been proposed
to be responsible for extracellular matrix (e.g., collagen) overproduction and fibrosis occurring in chronic respiratory diseases such as idiopathic pulmonary fibrosis [II, 12], asthma [13], the chronic obstructive pulmonary disease (COPD) [14], and obliterative bronchiolitis [4]. Genetic lineage studies in diseases such as idiopathic pulmonary fibrosis [11, 12], asthma overproduction and fibrosis occurring in chronic respiratory to be responsible for extracellular matrix (e.g., collagen) synthesis by epithelial cells are a major source of progenitor cells for repair of the injured airway [15]. Alveolar cells undergoing EMT become dedifferentiated, capable of both self-renewal and formation of fibroblastic foci, with the latter constituting sites of active fibrogenesis. EMT-activated alveolar epithelial cells synthesize a variety of fibrogenic cytokines, including TGFβ, TNFα, endothelin-1 and connective tissue growth factor (CTGF) [16], ECM components (Col 1A), and matrix metalloproteases (MMPs), all contributing to the pathological extracellular matrix remodeling. The process of dysregulated EMT has also been implicated in cancer progression. Here, EMT transition promotes growth factor independence, resistance to chemotherapeutic agents, and acquisition of stem-cell-like phenotype. These latter events are partly responsible for the maintenance of cancer and metastatic behavior.

Mechanistic studies have shown that EMT is initiated by a wide variety of agents linked to chronic inflammation including oxidative stress (ROS) [16], growth factors (TGF, EGF, and IGF) [17], and cytokines (TNFα). In the airways, these factors are produced by injured epithelial cells, fibroblasts, and eosinophils [18]. The prototypical inducer of type II EMT is TGFβ1, a cytokine master regulator that induces EMT via the canonical TGFβR1-Smad3-dependent signaling pathway [13]. The TGFβ-Smad3 pathway activates downstream Wnt, notch, and NF-κB signaling pathways to coordinate the complex genetic changes underlying EMT [19]. The core transcriptional regulators of the EMT program include the transcriptional regulators SNAIL (SNAI)1/2, Zebra (ZEB), Twist, and FOXC2 proteins. These factors coordinate acquisition of the mesenchymal phenotype through (1) downregulation of epithelial cadherin (E-Cad) involved in maintenance of cell polarity, (2) induction of intermediate filament proteins such as vimentin, (3) activation of small GTPases (to induce motility), and (4) expression of matrix metalloproteinasises (MMPs) and collagen to induce fibrogenesis. Although EMT can be reversible, stable EMT is maintained through global epigenetic reprogramming, including the reorganization (and increase) of the transcriptionally active histone (H3) Lys (K) 36 trimethyl marks within large organized heterochromatin domains [20].

In addition to their central role in airway repair, epithelial cells also function as sentinel cells to trigger innate host response to microbial and nonmicrobial challenges/invasion [21]. These cells are activated by a plethora of processes including pathogen-associated molecular patterns (PAMPs) [22]. The presence of PAMPs triggers the innate intracellular signaling pathways, converging on the NF-κB and IRF3 signaling pathways [23]. Of these, the NF-κB signaling pathway is composed of two coupled pathways known as the canonical and noncanonical pathways, distinguished by the regulatory kinase and different cytoplasmic reservoir from which NF-κB is activated [23–25]. In the rapidly activated canonical pathway, induced within minutes of stimulation, sequestered RelA-50 kDa NF-κB1 heterodimers in the cytoplasm are liberated and enter the nucleus to activate numerous genes including proinflammatory and antiapoptotic ones [26–28]. By contrast, the slower noncanonical NF-κB pathway, induced within hours of stimulation, is mediated by MAP3K14/NF-κB-inducing kinase (NIK)-IKKα complex that processes the 100 kDa precursor into 52 kDa NF-κB2 (p52), liberating the RelA-p52 heterodimer for nuclear import. We have recently shown that the slower noncanonical NF-κB pathway is linked to the canonical pathway by a feed-forward module consisting of the TNF receptor (TRAF)-1 factor that complexes with, stabilizes, and activates the NIK-IKKα complex [24]. The noncanonical pathway induces expression of a temporally and biologically distinct group of genes [27].

The complex phenotype produced by EMT is beginning to be examined using an unbiased profiling coupled with computational inference [29]. Although the mechanism of inducing EMT has been extensively explored, much less is known about the effect of EMT on the network of innate inflammatory signaling pathways. By interrogating a primary human airway epithelial cell model of type II EMT using a multiplex gene expression profiling platform, we describe here how EMT perturbs the innate response. Here, we observe that the EMT phenotype dramatically affects the kinetics and patterns of the innate response. Remarkably, alterations in the NF-κB pathway are mediated by transcriptional elongation mediated by enhanced phospho-Ser carboxy terminal domain (CTD) of RNA Pol II binding to innate gene promoters. Dynamic deterministic modeling shows that the accelerated expression of TRAF1 and NF-κB2 in a coordinated IRES-dependent manner produces a shorter canonical-noncanonical NF-κB coupling constant. These studies suggest that a global analysis of the EMT phenotype can be further examined using computational deterministic modeling, multidimensional profiling, and analysis of large-scale chromatin structure.

2. Materials and Methods

2.1. RNA Extraction and Quantitation. Total cellular RNA was extracted using either RNasequeous phenol-free total RNA isolation kits (Life Technologies, CA) or Quick-RNA MiniPrep kits (Zymo Research) according to the manufacturer's recommendations. RNA was quantitated spectrophotometrically using a NanoDrop ND-1000 (NanoDrop Technologies, DE). The quality of the purified RNA was assessed by the visualization of 18S and 28S RNA bands using an Agilent BioAnalyzer 2100 (Agilent Technologies, CA). The resulting electropherograms were used in the calculation of the 28S/18S ratio and the RNA integrity number [30].

2.2. Assay Design and Validation. Real-time quantitative RT-PCR (QPCR) assays were designed from the coding sequence (CDS) of the gene of interest (NCBI), and exon-exon junctions were mapped via BLAT [31]. Whenever possible, at least one of the two PCR primers was designed to transcend an exon-intron junction in order to reduce
the potential impact of genomic DNA contamination in the surveyed RNA samples. Primers were designed using Primer Express 2.0 (Applied Biosystems) with default settings (Primer T<sub>m</sub> = 58°C–60°C, GC content = 30–80%, Length = 9–40 nucleotides, and Amplicon Length = 90–150 nucleotides). Primers were synthesized (IDT) and reconstituted to a final concentration of 100 μM (master stock) and a working stock of 5 μM. Specificity of each assay was confirmed via PCR under the reaction conditions listed below and analyzed by PAGE. A reverse transcriptase minus control was included to determine the existence of signal contribution from genomic DNA. Assays were formatted using a 96-well platform.

2.3. Real-Time QPCR Analysis of Gene Expression. Reverse transcription was performed on 1 μg of total RNA with random primers, utilizing TaqMan reverse transcription reagents (Applied Biosystems) under conditions recommended by the manufacturer. Although the mass of input RNA should not be utilized for normalization purposes, the amounts of input RNA to be assayed were equivalent. The reverse transcription product was used as a template for the subsequent PCR reaction, consisting of SYBR Green PCR Master Mix, template cDNA, and assay primers (Table 1) in a total reaction volume of 25 μL. Thermal cycling (50°C, 2 min; 95°C, 10 min; and 40 cycles at 95°C, 15 S; 60°C, 1 min) was performed using an ABI prism 7500 sequence detection system (Life Technologies, CA). Threshold cycle numbers (C<sub>T</sub>) were defined as fluorescence values, generated by SYBR Green binding to double stranded PCR products, exceeding baseline. Relative transcript levels were quantified as a comparison of measured C<sub>T</sub> values for each reaction, normalized using a reference assay for human polymerase beta (NM_002690; Fwd: 5'ACAATCAATGAGTACACCATCCGT3'; Rev: 5'TCTCGGAACTCGAGTGACTCC3') and compared to those of a "control sample" (SAEC TGFβ minus) [32].

2.4. Cell Culture and EMT Transformation. The primary (nonimmortalized) human small airway epithelial cell (HSAEC) was purchased from Lonza. An immortalized cell line was established by infecting primary HSAECs with human telomerase (hTERT) and cyclin dependent kinase (CDK) 4 expressing retrovirus constructs and selecting under 250 ng/mL puromycin and 30 μg/mL G418 as described in [33]. The immortalized HSAECs were grown in small airway epithelial cell growth medium (SAGM; Lonza, Walkersville, MD) in a humidified atmosphere of 5% CO<sub>2</sub>. The immortalized HSAEC shows characteristics of normal cells such as contact inhibition of growth and failure to form soft agar colonies or form tumors in immune compromised mice. Immortalized human bronchial epithelial cells (HBEC) were grown in Keratinocyte serum-free medium (K-SFM, Life Technologies. Grand Island, NY) as described previously [33]. A549 cells were grown in RPMI supplemented with 5% fetal bovine serum. For induction of EMT, cells were TGFβ treated for 5 d (10 ng/mL, R&D systems, Minneapolis, MN) in the growth medium.

2.5. Dual Cross-Link Chromatin Immunoprecipitation (XChIP). XChIP was performed as described previously [34, 35]. A549 cells (~6 x 10<sup>5</sup> per 100-mm dish) were washed twice with PBS. Protein-protein cross-linking was first performed with disuccinimidyl glutarate (2 mM, Pierce), followed by protein-DNA cross-linking with formaldehyde. Equal amounts of sheared chromatin were immunoprecipitated overnight at 4°C with 4 μg of the indicated Ab in ChIP dilution buffer. Immunoprecipitates were collected with 40 μL protein A magnetic beads (Dynal Inc.), washed, and eluted in 250 μL elution buffer for 15 min at room temperature. Samples were de-cross-linked in 0.2 M NaCl at 65°C for 2 h. The precipitated DNA was phenol-chloroform extracted, precipitated with 100% ethanol, and dried.

Gene enrichment in XChIP was determined by quantitative real-time genomic PCR (Q-gPCR) as previously described [34] using region-specific PCR primers (Table 1). Standard curves were generated using a dilution series of genomic DNA (from 1 ng to 100 ng) for each primer pair. The fold change of DNA in each immunoprecipitated was determined by normalizing the absolute amount to the input DNA reference and calculating the fold change relative to that amount in unstimulated cells.

2.6. Deterministic Mathematical Modeling and Simulations. The deterministic mathematical model for both canonical and non-canonical arms of NF-κB pathway is recently published where we have shown that TRAF1-NIK acts as a central, rate-limiting feed-forward signaling complex to activate noncanonical pathway [24]. The complete model consists of 28 ordinary differential equations (ODEs) and 58 parameters. The expression of genes in the canonical pathway is RelA-dependent, whereas, the noncanonical pathway genes are p52-dependent. We observed that there is a time delay in TRAF1 translation by nearly 120 min. Likewise, a delay of 90 min between NFκB2 mRNA expression and translation has been reported earlier [36]. To examine the functional significance of these time delays in noncanonical pathway coupling, we performed different sets of simulations. In each simulation, the time delay function of TRAF1 and NFκB2 translation was altered by the addition or subtraction of 15 min on either side of nominal value, while keeping the translation rate the same in each simulation. These simulations covered the time delay span of 0–10 h for both TRAF1 and NFκB2 to study the effects of increasing and decreasing translation times on noncanonical pathway gene expression. In one set of simulations, we perturbed the system by varying the time-delay function of either TRAF1 or NFκB2 one at a time and keeping all other rate constants at nominal values. In another set, we perturbed the system by varying these time-delay functions of both TRAF1 and NF-κB2 simultaneously while keeping all other rate constants at nominal values. While the first set generated 42 such simulations for each protein, the second set generated more than 1600 such simulations. The latter will determine the synergistic effect of TRAF1 and NF-κB2 on the gene expression of the noncanonical pathway.
| Pathway                | Gene   | Accession # | Amplicon (bp) | Forward (5’-3’)                              | Reverse (5’-3’) |
|------------------------|--------|-------------|---------------|-----------------------------------------------|-----------------|
| **Canonical**          |        |             |               |                                               |                 |
| NFKBIA                 | NM_020529 | 116         | CCGCAGGAGGTGCGG | ATCACCTCCATGTTAGTGGCC                       |                 |
| CXCL2/GroB             | NM_002089 | 100         | ATTCACCTCAAAGACCTCAAAATG | GCCACATCTTGAGTGGCTGAT |                 |
| TNAIP3/A20             | NM_0027508 | 111         | GAAACACTTCACAACCTCTTCACC | CTCCGGCCTGGCTGGCTGTC |                 |
| IL-6                   | NM_000600 | 90          | CTGAGTTAATGAGAGACTGTC | TCAAAATCTGTTCTGGAGGGTACTCTAGG |                 |
| IL-8                   | NM_000584 | 92          | AAGACATACCTCAAAACCTTTCCC | CAATAATCTCCTGTTGGCCGA |                 |
| **Noncanonical EMT**   |        |             |               |                                               |                 |
| TNFIP1                 | NM_00125385 | 92         | ATCCAGTGCCACCTCTGGT | CCAAGCGCAGATTCCAT |                 |
| SMA/ACTA2              | NM_0014945 | 91          | TGTAAGGCGCTTTTCTC | TTCACCATACCCCT |                 |
| CollA1                 | NM_0000888 | 95          | CCAAAGAGACTGTTACATCAGCA | GGCCTACTCGAAGAGACTGGA |                 |
| Vimentin               | NM_003380 | 91          | GCTCAATGTTAAGATGTTCC | TGGAGAGAGAAGAGATCCTG |                 |
| Desmin                 | NM_0012927 | 91          | GGAGAGAGAGCCGGATTCA | GAGGCTACTAGG |                 |
| Twist1                 | NM_000474 | 101         | TTCCAGGAGCTTCAGAATCC | GAATGACATTCTAGGCTGTC |                 |
| Twist2                 | NM_00123783 | 119        | ATCCAGGAGCTTTTCTC | GCCACCATACCCCT |                 |
| SLUG                   | AF084243 | 91          | GCATGGACTCTAACGAGC | ACTGACTGCCCACCAATGAT |                 |
| SNAI1                  | NM_005985 | 95          | GCCTCTTCTCTCCTCTGG | GGCCTACAGGAAAGTACTC |                 |
| ITGA2                  | NM_0022503 | 91          | AGCCAGAATGCAACAGAATGATATA | GGCAGCTCTTCCATAAATGC |                 |
| FSP1/S100A4            | NM_0014945 | 91          | ATCCAGGAGCTTTTCTC | GCCACCATACCCCT |                 |
| SMA/ACTA2              | NM_0014945 | 91          | ATCCAGGAGCTTTTCTC | GCCACCATACCCCT |                 |
| **IFN**                |        |             |               |                                               |                 |
| IFNγ                   | NM_0002176 | 95          | GCATTCCACAAGAGAGAGGAC | TCCACAGCTGATGATGAT |                 |
| IFNα6                  | NM_0020102 | 91          | GTGGTGTCCAGGGTCAAGTC | CCAAGGACATGCTTCCTC |                 |
| IFNα21                 | NM_0002175 | 91          | GTAGTCCTGCACAGGACAGA | TTTCACAGGAGAAGAGGAG |                 |
| CCL5/RANTES            | NM_002895 | 96          | TCTAAGGATTGAAGATGATGCGCT | CCAGGAAACAGGTTTCTCTG |                 |
| DDX58/RIG1             | NM_0013434 | 132         | CACCTTTAAACCCAGAGAGAATACAA | TTCCACAGGTCACGCTATGAT |                 |
| LMP2                   | NM_0002800 | 91          | TCTCAGGACTGCTCAAGAG | CCAAGCCGACGGTAG |                 |
| TAPI                   | NM_0005959 | 91          | GGTTTCTTAACAGGACCCAGAGAGA | GCTAGTATTCCACTAGGAATCCT |                 |
| **STAT**               |        |             |               |                                               |                 |
| STAT2                  | NM_0007315 | 104         | TCCATGTCGCGTTCAGTGGT | GGTGTCACACGCTGCTG |                 |
| IRF1                   | NM_0021982 | 91          | CAGCACCAAGAAGGCTACTGTCAG | TTCATGTCGCTG |                 |
| IRF9                   | NM_006084 | 91          | AGGCCAGAAGGCTACTGTCAGAGAA | GCTAGTGTAAGTTCGCTGTCG |                 |
| SOCS3                  | NM_0003955 | 91          | CTTCAGGTCGCGTTCAGTGGT | GACGAGACGCTGCTG |                 |
| IFI27                  | NM_001130080 | 91     | CAGATCTAGGGCATGCAATCTGGA | GCGGAGAGAGAATTGTCG |                 |
| MX1                    | NM_001144295 | 106 | GAAACACCACTAAGGATGAGGAT | ATGTTGATGAGCTCTGCGT |                 |
| IFN1L (IL-29)          | NM_172140 | 103         | AAGCCCAAGACATGCTG | ACTTCTTCGAGGGTCC |                 |
| IFN1L (IL-28A)         | NM_172138 | 101         | ATGACGACGGGACTGAC | ATCCAGGAGAGCCGCTG |                 |
| IFN1L (IL-28B)         | NM_172139 | 99          | ATGACGACGGGACTGAC | ATCCAGGAGAGCCGCTG |                 |
| **Growth factor**      |        |             |               |                                               |                 |
| Fos                    | NM_005252 | 91          | GGGCAAGGAGTGGGAACTTATC | GGTGGCGGATTTGCTGCTG |                 |
| c-Jun                  | NM_0022282 | 91          | GCTCAGGAGAGGATGACAG | GGGCGGTTCCAGGCTGCTCC |                 |
| SOD2                   | NM_000636 | 90          | TTGGTTTGCCAAATCAGGATCC | TGAAGTGTAAGTGGTGCT |                 |
| TM4SF1                 | NM_0014220 | 91          | GAGGTGGCTGGCTGAGTGT | CCACTTGTGTCGAGCAG |                 |
| Pathway    | Gene   | Accession # | Amplicon (bp) | Forward (5'-3')          | Reverse (5'-3')             |
|------------|--------|-------------|---------------|--------------------------|-----------------------------|
| ROS/DNA    | NOX1   | NM_007052   | 91            | GGGCATCCCCCCTGAGTCT      | TCTGCTGGAAGCGGTAACAC        |
|            | NOX4   | NM_016931   | 91            | ACTCAACACCCCTGTTGGATGACT | CCAACGGAAGGACTGGATATCT      |
|            | HOXB9  | NM_024017   | 91            | GCCCGGATCAAACCAACC       | TCCAGCGTCTGGTATTTGGTG       |
|            | ATM    | NM_000051   | 127           | GCTTCTCAGGATAATCCCGAAG   | CCAAGCAGCTTCCAACAGC         |
|            | STK39 (SRT39) | NM_013233 | 91            | GCCCAAGAGCCAAAAGGT       | CGTCGTCACTCCACTCCA          |
| Cell cycle | PCNA   | NM_002592   | 91            | TGGGGCGCGAAATGA          | CTTTCCTGTTTGGGTCTTC         |
|            | CDKN1A | NM_000389   | 92            | AGCAGGCTGAAAGGTCCC       | GCGTTGGAGTGTAAGAAATCTGT     |
2.7. Clustering Approaches. A clustered image map (CIM) of a normalized matrix was created that correlates gene expression pattern to different time points in HSAECs cells upon stimulation by TNFα and TGFβ. For each gene, mean and standard deviation were calculated from their expression fold changes (see Table S1 in Supplementary Material available online at http://dx.doi.org/10.1155/2013/505864) across the time course and were normalized to unstimulated HSAECs [26–28]. Z-score transformation was calculated for each of the 50 genes (Table S2) by subtracting each fold change value by the row mean and dividing by the row standard deviation [37]. In essence, the Z-score gives an estimation of the deviation of the measurement from the row mean in standard deviation units. Hierarchical clustering was performed using an average-linkage clustering algorithm across six different time points in the absence or presence of stimulants. The cluster tree of genes is represented on the y-axis, and time-points and stimulants are shown on the x-axis. Each block of red or green represents a high positive or negative correlation between the gene expression and the stimulant under a specific time point.

3. Results and Discussion

3.1. Induction of Type II EMT. To establish a model of type II EMT, a continuously replicating line of human small airway epithelial cells was generated by immortalization using human telomerase (hTERT) and CDK4 expression [33]. These cells show a stable epithelial morphology and differentiated cytokeratin isofoms after over 100 population doublings, express the stem cell marker p63 and high levels of p16INK4A, and have an intact p53 checkpoint pathway [33].

To characterize type II EMT, HSAECs were incubated in the absence or presence of TGFβ (5 ng/mL) for 10 d. Transformed type II alveolar epithelial cells (A549) and immortalized bronchial epithelial cells (HBECs) were used as reference. Cells were fixed, stained with FITC-conjugated phalloidin (for distribution of F-actin) and DAPI (a nuclear stain), and examined by confocal microscopy. In the absence of TGFβ stimulation, HSAECs assumed a normal cuboidal morphology with perinuclear cytoplasmic distribution of F-actin (Figure 1(a)). By contrast, TGFβ-treated HSAECs showed an elongated shape with markedly induced F-actin staining (Figure 1(a)). This morphological change of enhanced front-rear polarity and cytoskeletal actin rearrangement are similar to those observed in TGFβ-treated A549 and HBECs; all are characteristic morphological changes of EMT [8].

To further confirm the induction of EMT, expression of ECM genes and EMT-associated transcription factors were assessed by Q-RT-PCR. TGFβ-treated HSAECs showed marked upregulation of extracellular matrix (ECM; Col1A), mesenchymal intermediate filament protein (vimentin), and TGFβ-induced transcription factors (SNAI1, Twist1/2) mediating the EMT genetic program (Figure 1(b)). This gene expression pattern is similar to those observed in other primary epithelial cells [13]. Together, these data suggest that TGFβ induces morphological and gene signatures of stable type II EMT in HSAECs.

3.2. Systems Profiling. Our goal was to establish a platform for the systematic perturbation of the signaling phenotype induced by stable type II EMT using reiterated rounds of stimulus perturbations and profiling measurements to inform the development of predictive models of complex behavior (schematically illustrated in Figure 2). For these experiments we developed a quantitative plate-based PCR assay to monitor the signature gene expression of the innate pathway, including the interferon, canonical and noncanonical NF-κB dependent pathways, the DNA damage response pathways, the EMT programs, JAK/STAT pathway, and growth factor pathways (Table 1).

3.3. Perturbations of Signaling Dynamics in Response to EMT. The time series experiments of the gene expression driven by the canonical NF-κB pathway were measured by using plate-based Q-RT-PCR in control and EMT-transformed HSAECs in response to the prototypical activating cytokine, TNFα. Relative changes in mRNA expression were normalized to DNA polymerase β as a housekeeping gene, and the data were Z-score-transformed to show deviations of expression in standard deviation units [26, 37]. The gene expression of the pathway was then visualized using hierarchical clustering (Figure 3, and Supplemental Tables). The HSAECs after EMT showed unique quantitative and qualitative expression patterns. For example, the top cluster contains members of the interferon-gamma (IFN) pathway such as ITGA2, myxovirus resistance 1 (MX1), signal transducer and activator of transcription (STAT1), proteasomal components low molecular weight proteins (LMP2), and transporters associated with antigen processing (TAP2); these genes are markedly downregulated as a function of EMT (Figure 3). By contrast, genes within the NF-κB pathway, growth factor response, and EMT signatures were markedly upregulated (Figure 3).

3.4. EMT Effects on the Canonical NF-κB Signaling Pathway. Because of the marked effects of the EMT state on the NF-κB pathway, we sought to further investigate this mechanism. Hierarchical clustering of the NF-κB-dependent gene pathway is shown in Figure 4. Genes that selectively respond to the canonical pathway include NFKBIA/IκBα and TNFAIP3/A20; we have shown that the expression of these genes depends on IκBα proteolysis and that they have direct NF-κB/IκBα binding sites in their promoters [26, 38]. Greater upregulation of these genes was observed at the earliest time point measured, with a second wave of expression at 12–24 h after TNFα stimulation. This mimics the oscillatory behavior of the NF-κB signaling pathway observed in cancer cells [39].

3.5. EMT Affects the Coupling of the Noncanonical to the Canonical NF-κB Signaling Pathways. EMT effects on the time-dependent expression of the TNIP1/Naf1 gene, a hallmark of the noncanonical NF-κB pathway [24, 27], were also evident in the hierarchical clustering (Figures 3 and 4).
Figure 1: TGFβ induces EMT transition in HSAECs. (a) F-actin staining. Shown in green is a confocal microscopic image of FITC-phalloidin staining merged with DAPI staining (blue) of HSAECs, A549 cells, and HBECs in the absence or presence of TGFβ stimulation as indicated. (b) Expression of EMT program. Shown is normalized mRNA expression in HSAECs in the presence or absence of EMT after 10 d of TGFβ treatment. For each gene, mRNA expression was normalized to β-pol as a housekeeping gene and expressed as the fold change relative to its expression in the absence of TGFβ stimulation. Shown is mean and SE of replicate measurements. Each point is the mean of a duplicate biological experiment, measured with three technical replicates. Abbreviations: SLUG, Snail2; SNAL1, Snail1; col1A, collagen type 1a.

Figure 2: Systems approach to understanding EMT phenotypes. Schematic diagram of approach to understanding EMT phenotype using profiling and bioinformatics inferences. * indicates all the techniques/concepts that have been used in the current study, whereas others will be conducted in future studies.
As discussed above, the noncanonical pathway is coupled to the canonical pathway through the expression of TNF receptor associated factor-1 (TRAF-1). TRAF-1 is unique for the TRAF isoforms that complexes with, stabilizes, and activates the NIK-IKKα complex to trigger the noncanonical pathway [24]. Analysis of relative fold change of expression showed that TRAF-1 expression was strongly upregulated within 1h of TNFα stimulation and peaked at 12h in EMT-HSAECs versus HSAECs, whereas, TRAF-1 was upregulated by 20-fold at 12h after TNFα stimulation in EMT-HSEACs versus 3-fold in HSEACs (Figure 5(a)). We especially noted that the noncanonical NF-κB pathway-dependent TNIP1/Nafl gene showed a leftward shift in the temporal expression profile, where, in the presence of EMT, TNIP1/Nafl expression was more rapidly induced, reaching the plateau within 3h of stimulation in the EMT-HSAECs versus the 6h required to reach plateau seen in HSAECs (Figure 5(a)). Together, these data indicate that EMT induces more robust expression of TRAF1 and produced a rapid coupling of the canonical to the noncanonical NF-κB pathway.

3.6. EMT Effects on Chromatin Modification and Transcriptional Elongation. Transcription of protein-coding genes by RNA Pol II is a highly regulated process involving preinitiation (assembly of basal transcription factors and co-activator recruitment), leading to initiation, elongation, and termination phases of RNA synthesis [40]. Previous work by our group and others has shown that transcriptional elongation is
a major regulated event controlling the innate response [38, 41, 42]. Because genome-wide analysis of EMT has revealed that TGFβ induces global reorganization of transcriptionally active marks (histone (H3) Lys (K) 36 trimethyl) in large organized heterochromatin domains [20], we examined whether the NF-κB-dependent genes were affected by chromatin remodeling or via changes in transcriptional elongation. We therefore measured the binding of the transactivator (NFκB/RelA), transcriptional elongation complex (CDK9), activated transcriptional elongation polymerase (phospho-Ser2 RNA Pol II), and euchromatin marks (H3K4Me3) on the TRAF-1 promoter using a highly quantitative two-step chromatin immunoprecipitation (XChIP) assay [34, 43]. Here, TNFα induced a similar level of increase in NF-κB/RelA binding to promoter in both EMT-HSAECs and normal HSAECs. This induction of NF-κB/RelA binding was not affected by EMT (Figure 5(b)). TNFα stimulation induced a significant increase in phospho-Ser2 RNA Pol II binding in the EMT-HSAECs, despite reduced amounts of CDK9 binding in both basal and TNFα stimulated conditions (Figure 5(b)). EMT induced the level of H3K4Me3 binding to the TRAF1 promoter, even in the absence of TNFα stimulation. Together, these findings indicate that EMT promotes remodeling of the chromatin environment of the TRAF1 gene, poising it for more rapid induction via transcriptional elongation.

3.7. Computational Simulations of the Effect of EMT on Canonical-Noncanonical NF-κB Coupling. We previously reported a deterministic mathematical model linking the canonical and noncanonical arms of NF-κB pathway, where we have shown that the formation of the TRAF1-NIK complex acts as a rate-limiting feed-forward signaling complex necessary to activate the noncanonical pathway [24]. Based on the time delay between the expression of TRAF1 mRNA and TRAF1 protein and the presence of an atypical internal ribosomal binding site (IRES) and translational initiation site at an internal site in TRAF1 [44], we predicted that a delay in TRAF1 protein translation via a cap-independent mechanism controls the rate of noncanonical NF-κB pathway activation in response to TNFα. Interestingly, our expression profiling data here suggest that pathway coupling is affected by EMT in the HSAECs. Through the enhanced formation of transcriptional elongation-competent RNA Pol II, TRAF1 and NF-κB2 expression is enhanced, resulting in a shift of noncanonical pathway activation (TNIP1/Naf1) to earlier times.
Figure 5: Continued.
Figure 5: Effect of EMT on canonical-noncanonical NF-κB pathway coupling. (a) Relative changes in TRAF1, NF-κB2, and TNIP1 mRNA expressed as fold-change measurements in the absence or presence of TGFβ-induced EMT as indicated. Each point is the mean of a duplicate biological experiment, measured with three technical replicates. (b) XChIP experiments of HSAECs in the presence (grey bars) or absence (black bars) of TGFβ-induced EMT. Shown is fold change in the TRAF1 promoter quantified by Q-gPCR relative to unstimulated HSAEC signal in duplicate experiments. (c) Computational simulations of p52 processing as a function of translational delay for TRAF1 and NFκB2. Abbreviations; T.d., translational delay. (A) shows the effect of increasing TRAF1 translational delay on p52 processing time while keeping the translational delay of NFκB2 either at nominal rate (90% T.d) or higher than nominal rate or lower than nominal rate. (B) shows similar effect but for increasing NFκB2 translational delay (x-axis). (C) shows the contour plot of all simulations (D, E) amantadine-treated A549 cells (200 μg/mL) were stimulated with poly I:C and TNIP1/Naf1 (D), and IL8 (E) expression was measured by Q-RT-PCR. Data expressed as fold change as compared to untreated cells after normalizing to internal controls, GAPDH. Data analyzed by a 2-way ANOVA with multiple comparisons. Significantly different from amantadine untreated samples: *P < 0.05 and **P < 0.001. Amantadine-treated cells (light bars) showed higher level of noncanonical pathway inhibition compared to untreated cells (dark bars).
We, therefore, performed simulations of the noncanonical pathway coupling by systematically varying the translational delay function of TRAF1. Interestingly, the coupling interval, that is, time lag between the activation of canonical NF-κB pathway and the formation of p52, monotonically reduced as TRAF-1 translation was increased until it reached a critical threshold of 90 min (Figure 5(c): (A)). Further reductions in the TRAF-1 translation delay function alone, even to zero, did not reduce the coupling interval for p52 formation and TNIP/Naf1 expression.

After examination of other proteins in the noncanonical pathway, we noted that NF-κB2 translation delay function produced a similar effect, where the coupling interval reached a plateau below which p52 processing was not further increased (Figure 5(c): (B)). In these experiments, a total of 42 simulations were conducted for each protein covering the time points from zero to 10 h.

The finding that the coupling interval was inert to reducing the translational delay of each protein individually prompted us to perform a simulation by changing the translational delay parameters for both TRAF1 and NF-κB2 simultaneously. The biological rationale for this is that TRAF-1 is translated by a cap-independent mechanism [44] and our previous studies show that both of these mRNAs are translated in a coordinated, delayed manner distinct from those mRNAs undergoing cap-dependent translation. A total of 1681 combinatorial simulations of the translational delay were conducted covering the time points from 0 to 10 h. Interestingly, we found that reducing the IRES-dependent translational delays for both proteins together resulted in shorter coupling interval (e.g., an earlier onset of p52 processing and noncanonical gene expression) to values as quickly as 15 min relative to TNFα stimulation (versus the nominal time of 6 h) (Figure 5(c): (A), (B)). In both figures, reducing the translational delay of both proteins to zero resulted in the early processing of p100 to p52. Figure 5(c): (C) shows the cumulative effect of all combinations of simulations for these two proteins. A conceptual representation is shown in Table 2. This model thus predicts that altering the translation rate of these two proteins produces a leftward shift in noncanonical gene expression kinetics relative to the canonical pathway.

Our computational model predicted that TRAF1 and p100 translation is under IRES-dependent control. Our earlier studies have shown that the activation kinetics of noncanonical pathway is coincident with that of the canonical pathway in response to viral infection and dsRNA stimulation [45]. We noted that the effects of dsRNA are similar to that of EMT by reducing the coupling constant between the canonical and noncanonical pathways. To confirm whether the noncanonical pathway was coupled to NF-κB/RelA through an IRES-dependent mechanism, we perturbed an IRES mediated translation using amantadine, a known inhibitor of IRES-dependent translation [46]. A549 cells were activated using poly I:C treatment in the absence or presence of amantadine, and canonical and noncanonical pathway kinetics were measured. We observed that the amantadine-treated cells showed significant inhibition of TNIP1/Naf1 expression compared to control cells (no amantadine treatment) after 4 and 6 h of treatment (Figure 5(c): (D)). At this dose, amantadine seems to have some inhibitory effect on IL8 expression at 6 h (Figure 5(c): (E)) although this effect was significantly lower than its effect on TNPI/Naf1 (7-fold versus 2-fold) (Figure 5(c): (D), (E)). These results suggest that EMT results in chromatin remodeling and transcriptional elongation of TRAF-1/NFκB2 expression as well as influencing the rate of translation of IRES-dependent genes, resulting in shortening the coupling interval between the canonical and noncanonical pathways (Figure 6).

### 4. Discussion

In this study, we applied systems level approaches to interrogate the dynamic state of EMT in a model of chronic mucosal inflammation. Although EMT processes (type I EMT) are essential during histogenesis and organogenesis, type II EMT is involved in organ remodeling and chronic diseases, and type III EMT is involved in progression of transformed epithelial cells to a metastatic phenotype. These newly formed mesenchymal cells transiently express distinct markers acquiring “front-rear” polarity, become invasive, and induce extracellular matrix remodeling. Using immortalized human small airway epithelial cells, we demonstrate that TGFβ induces stable EMT transition morphologically through the restructuring of actin cytoskeleton, induction of intermediate mesenchymal cytoskeletal proteins, and expression of the SNALI/Twist transcription factors. Although the signals conferring EMT have been extensively investigated, the effect of EMT on signal transduction pathways has not been systematically explored. Here, we investigated the effect of EMT on innate signaling and discovered that EMT dramatically affects two coupled arms of the NF-κB signaling pathway. This coupling is mediated through the induction of transcriptionally active euchromatin marks and enhancement of transcriptional elongation. Our computational simulations further predict that translational rate of these two key rate-limiting coupling proteins must also be affected. As a result, the innate pathway is hyperresponsive in type II EMT, with a more rapid coupling between the canonical and noncanonical arms of the NF-κB pathway. Because EMT has been observed in chronic lung fibrotic disease in humans [47] and epithelial cells isolated from human asthmatics undergo

| Time-delay combinations (min) | NF-κB2/p100 processing kinetics |
|-------------------------------|---------------------------------|
| (1) TRAF1 (<120) + P100 (<90) | Fast                            |
| (2) TRAF1 (≥120) + P100 (≥90) | Near nominal or nominal         |
| (3) TRAF1 (≥120) + P100 (≥90) | Delayed                         |

### Table 2: Conceptual representation of combinatorial simulations of translational delays of TRAF1 and NF-κB2.
Figure 6: Effect of EMT on canonical-noncanonical NF-κB coupling. Schematic diagram of EMT effects on NF-κB signaling pathway. EMT induces changes in euchromatin marks of NF-κB-dependent genes, transcriptional elongation, and translational delay to reduce the coupling constant between the NF-κB canonical and noncanonical pathways. A timeline is shown for both states of EMT-Basal (no EMT) and TGFβ-mediated EMT (0 to 6 h).
a greater degree of EMT than normal subjects [13], these studies have special relevance to airway pathophysiology.

Type II EMT may play a critical cellular role in the progression of human pulmonary fibrotic diseases. Although the molecular basis of airway remodeling and loss of epithelial integrity in asthma is still undefined, several lines of evidence implicate EMT in this process [48]. For example, the airway epithelium is recognized as an important contributor to intrapulmonary fibroblast accumulation after injury, including idiopathic pulmonary fibrosis [12, 49], asthma, and COPD [50]. The bronchial epithelium in asthma is highly abnormal with structural changes involving the separation of columnar cells from their basal attachment leading to the disruption of epithelial barrier and functional changes including increased expression and release of profibrotic factors [2]. Subepithelial fibrosis is influenced by epithelial cell-derived VEGF, IL-33, IL-25, and thymic stromal lymphopoietin (TSLP), as well as leukocyte-derived TGF-β. Epithelial cells from individuals with asthma produce high amounts of peristatin, a cytokine that stimulates TGF-β production and modifies myofibroblast collagen synthesis [51]. The increase in myofibroblasts causes thickening and increased density of the subepithelial basement membrane, contributing to a progressive decline in lung function [48, 52].

The relationship between epithelial fibrosis and innate inflammation is a complex and interrelated phenomenon. Specifically, the TNFα-NF-κB pathway has a number of modulatory actions on epithelial EMT. For example, activated NF-κB suppresses E-Cad and induces the expression of mesenchymal vimentin, two hallmarks of EMT [53]. Studies of insulin breast cancer epithelial cells have shown that like growth factor (IGF)1 receptor-induced EMT is partially mediated by NF-κB-increased expression of SNAI1 [54]. SNAI1 upregulation is mediated at multiple levels, including direct binding to the SNAI1 promoter leading to an increased mRNA expression at the level of transcription [55] and secondly by induction of CSN2, a protein that disrupts binding GSK-3β and β-Trcp binding to SNAI1 resulting in its posttranslational stabilization [56]. Our observations suggest that EMT-HSAECs express high levels of SNAI1, and that upregulation of NF-κB is partially responsible for mediating type II EMT. More work will be required to determine the requirement of NF-κB signaling in EMT of HSAECs. We note that other studies have shown that NF-κB activates ZEB in mammary epithelial cells through cis-regulatory elements in the ZEB promoter [53], perhaps suggesting that NF-κB is a master regulator of EMT programs.

An exciting and novel finding in our studies is that EMT sensitized the innate pathway to be hyperresponsive to its canonical activating signals. Specifically, we demonstrate that EMT dramatically upregulates innate genes and accelerates the coordinated induction of TRAF1 and NF-κB2 expression by modulating euchromatin marks and inducing transcriptional elongation. Our XChIP experiments indicate that genes downstream of the NF-κB pathway are regulated by a mechanism involving enhanced formation of phospho-SerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSerSer Ser
In summary, using RNA profiling of an EMT cell model, we demonstrate that this transition has dramatic effects on the induction of the innate pathway through a mechanism involving chromatin remodeling of the TRAF1 locus, enabling enhanced phospho-Pol II loading and transcriptional elongation. Computational simulation experiments suggest that rapid, coordinate, TRAF1/NFkB2 expression is coupled to their IRES-dependent translation. These rapidly expressed proteins produce a feed-forward mechanism that reduces the coupling interval between the canonical and noncanonical signaling arms of the NF-κB pathways. Further applications of systems approaches will promote a comprehensive understanding of this complex phenotype through reiterated rounds of gene perturbation, multidimensional profiling, and deterministic modeling.

Acknowledgments

This work was supported, in part, by the Sealy Center for Molecular Medicine, National Institute of Health Grants PO1 AI062885 (ARB, IB), NHLBI contract HHSN268201000037C (ARB, IB, KP) UL1TR00007, Clinical and Translational Science Award (ARB), GM086885 (ARB), and NC1 P50CA70907 (SPORE in Lung Cancer to JDM). The authors thank Rolf Konig, PhD, and Konrad Pazdrak, MD, PhD, for helpful discussions and input.

References

[1] A. J. Polito and D. Proud, “Epithelial cells as regulators of airway inflammation,” Journal of Allergy and Clinical Immunology, vol. 102, no. 5, pp. 714–718, 1998.
[2] B. N. Lambrecht and H. Hammad, “The airway epithelium in asthma,” Nature Medicine, vol. 18, pp. 684–692, 2012.
[3] B. C. Willis, J. M. Liebler, K. Luby-Phelps et al., “Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis,” The American Journal of Pathology, vol. 166, no. 5, pp. 1321–1332, 2005.
[4] C. Ward, I. A. Forrest, D. M. Murphy et al., “Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients,” Thorax, vol. 60, no. 10, pp. 865–871, 2005.
[5] S. G. Royce, L. Tan, A. A. Koek, and M. L. K. Tang, “Effect of extracellular matrix composition on airway epithelial cell and fibroblast structure: implications for airway remodeling in asthma,” Annals of Allergy, Asthma and Immunology, vol. 102, no. 3, pp. 238–246, 2009.
[6] D. E. Davies and S. T. Holgate, “Asthma: the importance of epithelial mesenchymal communication in pathogenesis: inflammation and the airway epithelium in asthma,” International Journal of Biochemistry and Cell Biology, vol. 34, no. 12, pp. 1520–1526, 2002.
[7] S. T. Holgate, J. Holloway, S. Wilson, F. Bucchieri, S. Puddicombe, and D. E. Davies, “Epithelial-mesenchymal communication in the pathogenesis of chronic asthma,” Proceedings of the American Thoracic Society, vol. 1, no. 2, pp. 93–98, 2004.
[8] R. Y. Huang, P. Guilford, and J. P. Thiery, “Early events in cell adhesion and polarity during epithelial-mesenchymal transition,” Journal of Cell Science, vol. 125, pp. 4417–4422, 2012.
[9] J. Lim and J. P. Thiery, “Epithelial-mesenchymal transitions: insights from development,” Development, vol. 139, pp. 3471–3486, 2012.
[10] B. C. Willis and Z. Borok, “TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease,” American Journal of Physiology, vol. 293, no. 3, pp. L525–L534, 2007.
[11] R. Jain, P. W. Shaul, Z. Borok, and B. C. Willis, “Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-β1,” American Journal of Respiratory Cell and Molecular Biology, vol. 37, no. 1, pp. 38–47, 2007.
[12] B. C. Willis, R. M. DuBois, and Z. Borok, “Epithelial origin of myofibroblasts during fibrosis in the lung,” Proceedings of the American Thoracic Society, vol. 3, no. 4, pp. 377–382, 2006.
[13] T.-L. Hackett, S. M. Warner, D. Stefanowicz et al., “Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-β1,” American Journal of Respiratory and Critical Care Medicine, vol. 180, no. 2, pp. 122–133, 2009.
[14] S. S. Sohal, D. Reid, A. Soltani et al., “Evaluation of epithelial mesenchymal transition in patients with chronic obstructive pulmonary disease,” Respiratory Research, vol. 12, p. 130, 2011.
[15] I. Y. Adamson, L. Young, and D. H. Bowden, “Relationship of alveolar epithelial injury and repair to the induction of pulmonary fibrosis,” The American Journal of Pathology, vol. 130, no. 2, pp. 377–383, 1988.
[16] S. Cannito, E. Novo, A. Compagnone et al., “Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells,” Carcinogenesis, vol. 29, no. 12, pp. 2267–2278, 2008.
[17] T. Vincent, E. P. Neve, J. R. Johnson et al., “A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-β mediated epithelial-mesenchymal transition,” Nature Cell Biology, vol. 11, no. 8, pp. 943–950, 2009.
[18] E. M. Minshall, D. Y. M. Leung, R. J. Martin et al., “Eosinophil-associated TGF-β1 mRNA Expression and airways fibrosis in bronchial asthma,” American Journal of Respiratory Cell and Molecular Biology, vol. 17, no. 3, pp. 326–333, 1997.
[19] J. Yang and R. A. Weinberg, “Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis,” Developmental Cell, vol. 14, no. 6, pp. 818–829, 2008.
[20] O. G. McDonald, H. Wu, W. Timp, A. Doi, and A. P. Feinberg, “Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition,” Nature Structural and Molecular Biology, vol. 18, no. 8, pp. 867–874, 2011.
[21] R. P. Garofalo and H. Haeberle, “Epithelial regulation of innate immunity to respiratory syncytial virus,” American Journal of Respiratory Cell and Molecular Biology, vol. 23, no. 5, pp. 581–585, 2000.
[22] S. Akira, S. Uematsu, and O. Takeuchi, “Pathogen recognition and innate immunity,” Cell, vol. 124, no. 4, pp. 783–801, 2006.
[23] A. R. Brasier, “The NF-kB signaling network: insights from systems approaches,” in Cellular Signaling and Innate Immune Responses to RNA Virus Infections, A. R. Brasier, S. M. Lemon, and A. Garcia-Sastre, Eds., pp. 119–135, American Society for Microbiology, 2008.
[24] S. Choudhary, M. Kalita, L. Fang et al., “Inducible TNF receptor associated factor 1 expression couples the canonical to the noncanonical NF-kB pathway in TNF stimulation,” The Journal of Biological Chemistry, vol. 288, pp. 14612–14623, 2013.
[25] A. R. Brasier, “The NF-kappaB regulatory network,” Cardiovascular Toxicology, vol. 6, no. 2, pp. 111–130, 2006.
[26] B. Tian, D. E. Nowak, M. Jamaluddin, S. Wang, and A. R. Brasier, “Identification of direct genomic targets downstream of the nuclear factor-κB transcription factor mediating tumor necrosis factor signaling,” The Journal of Biological Chemistry, vol. 280, no. 17, pp. 17435–17448, 2005.

[27] B. Tian, D. E. Nowak, and A. R. Brasier, “A TNF-induced gene expression program under oscillatory NF-κB control,” BMC Genomics, vol. 6, article 137, 2005.

[28] B. Tian and A. R. Brasier, “Identification of a nuclear factor KappaB-dependent gene network,” Recent Progress in Hormone Research, vol. 58, pp. 95–130, 2003.

[29] S. Thomson, F. Petti, I. Sujka-Kwok et al., “A systems view of γδ T cell expansion and functions in pulmonary fibrosis and is regulated by the extracellular matrix,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 35, pp. 13180–13185, 2006.

[30] A. Schroeder, O. Mueller, S. Stocker et al., “The RIN: an RNA integrity number for assigning integrity values to RNA measurements,” BMC Molecular Biology, vol. 7, article 3, 2006.

[31] W. J. Kent, “BLAT—the BLAST-like alignment tool,” Genome Research, vol. 12, no. 4, pp. 656–664, 2002.

[32] K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.

[33] D. E. Nowak, B. Tian, and A. R. Brasier, “Two-step cross-linking method for identification of NF-κB gene network by chromatin immunoprecipitation,” BioTechniques, vol. 39, no. 5, pp. 715–724, 2005.

[34] S. Basak, H. Kim, J. D. Kearns et al., “A fourth IκB protein within the NF-κB signaling module,” Cell, vol. 128, no. 2, pp. 369–381, 2007.

[35] C. Cheadle, M. P. Vawter, W. J. Freed, and K. G. Becker, “Analysis of microarray data using Z score transformation,” Journal of Molecular Diagnostics, vol. 5, no. 2, pp. 73–81, 2003.

[36] D. E. Nowak, B. Tian, M. Jamaluddin et al., “RelA Ser276 phosphorylation is required for activation of a subset of NF-κB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes,” Molecular and Cellular Biology, vol. 28, no. 11, pp. 3623–3638, 2008.

[37] D. E. Nelson, A. E. C. Ihekwaba, M. Elliott et al., “Oscillations in NF-κB signaling control the dynamics of gene expression,” Science, vol. 306, no. 5696, pp. 704–708, 2004.

[38] K. Chiba, J. Yamamoto, Y. Yamaguchi, and H. Handa, “Promoter–proximal pausing and its release: molecular mechanisms and physiological functions,” Experimental Cell Research, vol. 316, no. 17, pp. 2723–2730, 2010.

[39] A. R. Brasier, B. Tian, M. Jamaluddin, M. K. Kalita, R. P. Garofalo, and M. Lu, “RelA Ser276 phosphorylation-coupled Lys310 acetylation controls transcriptional elongation of inflammatory cytokines in respiratory syncytial virus infection,” Journal of Virology, vol. 85, no. 22, pp. 11752–11769, 2011.

[40] B. Tian, Y. Zhao, M. Kalita et al., “CDK9-dependent transcriptional elongation in the innate ISG response to RSV infection in airway epithelial cells,” Journal of Virology, vol. 87, no. 12, pp. 7075–7092, 2013.

[41] J. Yang, A. Mitra, N. Dojer, S. Fu, M. Rowicka, and A. R. Brasier, “A probabilistic approach to learn chromatin architecture and accurate inference of the NF-kappaB/RelA regulatory network using ChiP-Seq,” Nucleic Acids Research, vol. 41, no. 15, pp. 7240–7259, 2013.

[42] L. Yang, L. Gu, Z. Li, and M. Zhou, “Translation of TRAF1 is regulated by IRES-dependent mechanism and stimulated by vincristine,” Nucleic Acids Research, vol. 38, no. 13, pp. 4503–4513, 2010.

[43] Y.-J. Chen, S.-J. Zeng, J. T. Hsu et al., “Amantadine as a regulator of internal ribosome entry site,” Acta Pharmacologica Sinica, vol. 29, no. 11, pp. 1327–1333, 2008.

[44] H. Kasai, J. T. Allen, R. M. Mason, T. Kamimura, and Z. Zhang, “TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT),” Respiratory Research, vol. 6, article 56, 2005.

[45] C. G. Lee, B. Ma, S. Takyar et al., “Studies of vascular endothelial growth factor in asthma and chronic obstructive pulmonary disease,” Proceedings of the American Thoracic Society, vol. 8, no. 6, pp. 512–515, 2011.

[46] H. L. Chua, P. Bhat-Nakshatri, S. E. Clare, A. Morimya, S. Badve, and H. Nakshatri, “NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2,” Oncogene, vol. 26, no. 5, pp. 711–724, 2007.

[47] M. J. Barberá, I. Puig, D. Domínguez et al., “Regulation of Snail transcription during epithelial to mesenchymal transition of tumor cells,” Oncogene, vol. 23, no. 44, pp. 7345–7354, 2004.

[48] Y. Wu, J. Deng, P. G. Rychahou, S. Qiu, B. M. Evers, and B. P. Zhou, “Stabilization of Snail by NF-κB Is Required for inflammation-induced cell migration and invasion,” Cancer Cell, vol. 15, no. 5, pp. 416–428, 2009.
[57] A. R. Brasier, A. Garcia-Sastre, and S. M. Lemon, *Cellular Signaling and Innate Immune Response to RNA Virus Infections*, ASM Press, Washington, DC, USA, 2008.

[58] R. J. Sims III, R. Belotserkovskaya, and D. Reinberg, “Elongation by RNA polymerase II: the short and long of it,” *Genes and Development*, vol. 18, no. 20, pp. 2437–2468, 2004.

[59] B. M. Peterlin and D. H. Price, “Controlling the elongation phase of transcription with P-TEFb,” *Molecular Cell*, vol. 23, no. 3, pp. 297–305, 2006.

[60] S. Tourdot, S. Mathie, T. Hussell et al., “Respiratory syncytial virus infection provokes airway remodelling in allergen-exposed mice in absence of prior allergen sensitization,” *Clinical and Experimental Allergy*, vol. 38, no. 6, pp. 1016–1024, 2008.

[61] L. S. van Rijt, N. Vos, M. Willart et al., “Persistent activation of dendritic cells after resolution of allergic airway inflammation breaks tolerance to inhaled allergens in mice,” *American Journal of Respiratory and Critical Care Medicine*, vol. 184, no. 3, pp. 303–311, 2011.

[62] E. Kaltenborn, S. Kern, S. Frixel et al., “Respiratory syncytial virus potentiates ABCA3 mutation-induced loss of lung epithelial cell differentiation,” *Human Molecular Genetics*, vol. 21, pp. 2793–2806, 2012.

[63] C. Palena, D. E. Polev, K. Y. Tsang et al., “The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy,” *Clinical Cancer Research*, vol. 13, no. 8, pp. 2471–2478, 2007.